Bivalent probes of the human multidrug transporter P-glycoprotein

Biochemistry

Volumn 45, Issue 38, 2006, Pages 11695-11702

  Pires, Marcos M ^a   Hrycyna, Christine A ^a   Chmielewski, Jean ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; COMPOSITION EFFECTS; CYTOLOGY; DRUG PRODUCTS; HYDROPHILICITY; TOXICITY;

BIVALENT AGENTS; CYTOTOXIC AGENT; HYDROPHOBIC TETHERS; IODOARYLAZIDOPRAZOSIN;

PROTEINS;

ADENOSINE TRIPHOSPHATASE; CYCLOSPORIN A; CYTOTOXIC AGENT; DAUNORUBICIN; DIMER; DOXORUBICIN; EMETINE; GLYCOPROTEIN P; IODINE 125; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE 123; TRITIUM;

AMEBIASIS; ARTICLE; BINDING SITE; CANCER CHEMOTHERAPY; CARBON NUCLEAR MAGNETIC RESONANCE; CELL STRAIN MCF 7; CROSS LINKING; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIDRUG RESISTANCE; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ADENOSINE TRIPHOSPHATE; AZIDES; CROSS-LINKING REAGENTS; DIMERIZATION; DOXORUBICIN; EMETINE; FLOW CYTOMETRY; HUMANS; HYDROLYSIS; INHIBITORY CONCENTRATION 50; MODELS, BIOLOGICAL; MOLECULAR PROBES; P-GLYCOPROTEIN; PHOTOAFFINITY LABELS; PRAZOSIN; RHODAMINE 123; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 33749005414     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi0608109     Document Type: Article

References (47)

1. Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J., Roden, D. M., and Wilkinson, G. R. (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors, J. Clin. Invest. 101, 289-94.
2. Lee, C. G., Gottesman, M. M., Cardarelli, C. O., Ramachandra, M., Jeang, K. T., Ambudkar, S. V., Pastan, I., and Dey, S. (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter, Biochemistry 37, 3594-601.
3. Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., and Gottesman, M. M. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter, Annu. Rev. Pharmacol. Toxicol. 39, 361-98.
4. Gottesman, M. M., and Pastan, I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter, Annu. Rev. Biochem. 62, 385-427.
5. Gottesman, M. M., Hrycyna, C. A., Schoenlein, P. V., Germann, U. A., and Pastan, I. (1995) Genetic analysis of the multidrug transporter, Annu. Rev. Genet. 29, 607-49.
6. Hrycyna, C. A. (2001) Molecular genetic analysis and biochemical characterization of mammalian P-glycoproteins involved in multi-drug resistance, Semin. Cell Dev. Biol. 12, 247-56.
7. Oottesman, M. M., Fojo, T., and Bates, S. E. (2002) Multidrug resistance in cancer: Role of ATP-dependent transporters, Nat. Rev. Cancer 2, 48-58.
8. Huisman, M. T., Smit, J. W., Wiltshire, H. R., Hoetelmans, R. M., Beijnen, J. H., and Schinkel, A. H. (2001) P-Olycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir, Mol. Pharmacol. 59, 806-13.
9. Loscher, W., and Potschka, H. (2005) Drug resistance in brain diseases and the role of drug efflux transporters, Nat. Rev. Neurosci. 6, 591-602.
10. Schinkel, A. H., and Jonker, J. W. (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview, Adv. Drug Delivery Rev. 55, 3-29.
11. Borst, P., and Elferink, R. O. (2002) Mammalian ABC transporters in health and disease, Annu. Rev. Biochem. 71, 537-92.
12. Gottesman, M. M., and Pastan, I. (1988) The multidrug transporter, a double-edged sword, J. Biol. Chem. 263, 12163-6.
13. Higgins, C. F. (1992) ABC transporters: From microorganisms to man, Annu. Rev. Cell Biol. 8, 67-113.
14. Hrycyna, C. A., Ramachandra, M., Germann, U. A., Cheng, P. W., Pastan, I., and Gottesman, M. M. (1999) Both ATP sites of human P-glycoprotein are essential but not symmetric, Biochemistry 38, 13887-99.
15. Urbatsch, I. L., Beaudet, L., Carrier, I., and Gros, P. (1998) Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites, Biochemistry 37, 4592-602.
16. Loo, T. W., and Clarke, D. M. (1995) Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity, J. Biol. Chem. 270, 22957-61.
17. Raviv, Y., Pollard, H. B., Bruggemann, E. P., Pastan, I., and Gottesman, M. M. (1990) Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells, J. Biol. Chem. 265, 3975-80.
18. Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K., Borst, P., Nooijen, W. J., Beijnen, J. H., and van Tellingen, O. (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine, Proc. Natl. Acad. Sci. U.S.A. 94, 2031-5.
19. Illmer, T., Schalen, M., Platzbecker, U., Freiberg-Richter, J., Oelschlagel, U., von Bonin, M., Pursche, S., Bergemann, T., Ehninger, G., and Schleyer, E. (2004) P-Glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate, Leukemia 18, 401-8.
20. Archinal-Mattheis, A., Rzepka, R. W., Watanabe, T., Kokubu, N., Itoh, Y., Combates, N. J., Bair, K. W., and Cohen, D. (1995) Analysis of the interactions of SDZ PSC 833 ([3′-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein, Oncol. Res. 7, 603-10.
21. Farrell, R. J., Menconi, M. J., Keates, A. C., and Kelly, C. P. (2002) P-Glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes, Aliment. Pharmacol. Ther. 16, 1021-31.
22. Tsuji, A., Tamai, I., Sakata, A., Tenda, Y., and Terasaki, T. (1993) Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein, Biochem. Pharmacol. 46, 1096-9.
23. Dey, S., Ramachandra, M., Pastan, I., Gottesman, M. M., and Ambudkar, S. V. (1997) Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein, Proc. Natl. Acad. Sci. U.S.A. 94, 10594-9.
24. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2003) Methanethio-sulfonate derivatives of rhodamine and verapamil activate human P-glycoprotein at different sites, J. Biol. Chem. 278, 50136-41.
25. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2003) Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein, J. Biol. Chem. 278, 39706-10.
26. Shapiro, A. B., and Ling, V. (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities, Eur. J. Biochem. 250, 130-7.
27. Martin, C., Berridge, G., Higgins, C. F., Mistry, P., Charlton, P., and Callaghan, R. (2000) Communication between multiple drug binding sites on P-glycoprotein, Mol. Pharmacol. 58, 624-32.
28. Hyafil, F., Vergely, C., Du Vignaud, P., and Grand-Perret, T. (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative, Cancer Res. 53, 4595-602.
29. Dantzig, A. H., Shepard, R. L., Cao, J., Law, K. L., Ehlhardt, W. J., Baughman, T. M., Bumol, T. F., and Starling, J. J. (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979, Cancer Res. 55, 4171-9.
30. Mistry, P., Stewart, A. J., Dangerfield, W., Okiji, S., Liddle, C., Bootle, D., Plumb, J. A., Templeton, D., and Charlton, P. (2001) In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576, Cancer Res. 61, 749-58.
31. Wang, E., Casciano, C. N., Clement, R. P., and Johnson, W. W. (2001) The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein, Cancer Res. 61, 7525-9.
32. Newman, M. J., Rodarte, J. C., Benbatoul, K. D., Romano, S. J., Zhang, C., Krane, S., Moran, E. J., Uyeda, R. T., Dixon, R., Guns, E. S., and Mayer, L. D. (2000) Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multi-drug resistance, Cancer Res. 60, 2964-72.
33. Whitesides, G. M., Mammen, M., and Choi, S. (1998) Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem., Int. Ed. 37, 2754-94.
34. Hrycyna, C. A., Ramachandra, M., Pastan, I., and Gottesman, M. M. (1998) Functional expression of human P-glycoprotein from plasmids using vaccinia virus-bacteriophage T7 RNA polymerase system, Methods Enzymol. 292, 456-73.
35. Wang, E. J., Casciano, C. N., Clement, R. P., and Johnson, W. W. (2000) Two transport binding sites of P-glycoprotein are unequal yet contingent: Initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence, Biochim. Biophys. Acta 1481, 63-74.
36. Sauna, Z. E., Andrus, M. B., Turner, T. M., and Ambudkar, S. V. (2004) Biochemical basis of poly valency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: Stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy, Biochemistry 43, 2262-71.
37. Ambudkar, S. V., Kimchi-Sarfaty, C., Sauna, Z. E., and Gottesman, M. M. (2003) P-Glycoprotein: From genomics to mechanism, Oncogene 22, 7468-85.
38. Robert, J., and Jarry, C. (2003) Multidrug resistance reversal agents, J. Med. Chem. 46, 4805-17.
39. Wang, R. B., Kuo, C. L., Lien, L. L., and Lien, E. J. (2003) Structure-activity relationship: Analyses of P-glycoprotein substrates and inhibitors, J. Clin. Pharm. Ther. 28, 203-28.
40. Polli, J. W., Wring, S. A., Humphreys, J. E., Huang, L., Morgan, J. B., Webster, L. O., and Serabjit-Singh, C. S. (2001) Rational Use of in Vitro P-Glycoprotein Assays in Drug Discovery, J. Pharmacol. Exp. Ther. 299, 620-8.
41. Wolfe, M. S. (1982) The treatment of intestinal protozoan infections, Med. Clin. N. Am. 66, 707-20.
42. Ghosh, S. K., Lohia, A., Kumar, A., and Samuelson, J. (1996) Overexpression of P-glycoprotein gene 1 by transfected Entamoeba histolytica confers emetine-resistance, Mol. Biochem. Parasitol. 82, 257-60.
43. Loo, T. W., and Clarke, D. M. (2001) Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers, J. Biol. Chem. 276, 36877-80.
44. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2004) The drug-binding pocket of the human multidrug resistance P-glycoprotein is accessible to the aqueous medium, Biochemistry 43, 12081-9.
45. Borgnia, M. J., Eytan, G. D., and Assaraf, Y. G. (1996) Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its atpase activity, J. Biol. Chem. 271, 3163-71.
46. Al-Shawi, M. K., and Senior, A. E. (1993) Characterization of the adenosine triphosphatase activity of Chinese hamster P-glycoprotein, J. Biol. Chem. 268, 4197-206.
47. Farrell, R. J., Menconi, M. J., Keates, A. C., and Kelly, C. P. (2002) P-Glycoprotein-170 inhibition significantly reduces cortisol and cyclosporin efflux from human intestinal epithelial cells and T lymphocytes, Aliment. Pharmacol. Ther. 16, 1021-31.